249 related articles for article (PubMed ID: 26183319)
1. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Fleischer V; Sieber J; Fleischer SJ; Shock A; Heine G; Daridon C; Dörner T
Arthritis Res Ther; 2015 Jul; 17(1):185. PubMed ID: 26183319
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.
Giltiay NV; Shu GL; Shock A; Clark EA
Arthritis Res Ther; 2017 May; 19(1):91. PubMed ID: 28506291
[TBL] [Abstract][Full Text] [Related]
3. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.
Sieger N; Fleischer SJ; Mei HE; Reiter K; Shock A; Burmester GR; Daridon C; Dörner T
Arthritis Rheum; 2013 Mar; 65(3):770-9. PubMed ID: 23233360
[TBL] [Abstract][Full Text] [Related]
4. Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation.
Sieber J; Daridon C; Fleischer SJ; Fleischer V; Hiepe F; Alexander T; Heine G; Burmester GR; Fillatreau S; Dörner T
Arthritis Res Ther; 2014 Nov; 16(6):477. PubMed ID: 25385499
[TBL] [Abstract][Full Text] [Related]
5. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Dörner T; Shock A; Goldenberg DM; Lipsky PE
Autoimmun Rev; 2015 Dec; 14(12):1079-86. PubMed ID: 26212727
[TBL] [Abstract][Full Text] [Related]
6. Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22.
Özgör L; Brandl C; Shock A; Nitschke L
Eur J Immunol; 2016 Sep; 46(9):2260-72. PubMed ID: 27352780
[TBL] [Abstract][Full Text] [Related]
7. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.
Daridon C; Blassfeld D; Reiter K; Mei HE; Giesecke C; Goldenberg DM; Hansen A; Hostmann A; Frölich D; Dörner T
Arthritis Res Ther; 2010; 12(6):R204. PubMed ID: 21050432
[TBL] [Abstract][Full Text] [Related]
8. Cytokine panel and histopathological aspects in the systemic lupus erythematosus.
Avrămescu C; Biciuşcă V; Dăianu T; Turculeanu A; Bălăşoiu M; Popescu SN; Ionete O; Simionescu C
Rom J Morphol Embryol; 2010; 51(4):633-40. PubMed ID: 21103619
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
10. Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients with systemic lupus erythematosus.
Brink I; Thiele B; Burmester GR; Trebeljahr G; Emmrich F; Hiepe F
Lupus; 1999; 8(9):723-30. PubMed ID: 10602444
[TBL] [Abstract][Full Text] [Related]
11. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E2-mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice.
Chae BS; Shin TY; Kim DK; Eun JS; Leem JY; Yang JH
Arch Pharm Res; 2008 Apr; 31(4):503-10. PubMed ID: 18449509
[TBL] [Abstract][Full Text] [Related]
13. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
Chang CH; Wang Y; Gupta P; Goldenberg DM
MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
[TBL] [Abstract][Full Text] [Related]
14. B cells produce less IL-10, IL-6 and TNF-α in myasthenia gravis.
Yilmaz V; Oflazer P; Aysal F; Parman YG; Direskeneli H; Deymeer F; Saruhan-Direskeneli G
Autoimmunity; 2015 Jun; 48(4):201-7. PubMed ID: 25518708
[TBL] [Abstract][Full Text] [Related]
15. Correlation between TLR9 Expression and Cytokine Secretion in the Clinical Diagnosis of Systemic Lupus Erythematosus.
Rao H; Zeng Q; Liang Y; Xiao C; Xie S; Xu X
Mediators Inflamm; 2015; 2015():710720. PubMed ID: 26457008
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-10 response abnormalities in systemic lupus erythematosus.
Mongan AE; Ramdahin S; Warrington RJ
Scand J Immunol; 1997 Oct; 46(4):406-12. PubMed ID: 9350293
[TBL] [Abstract][Full Text] [Related]
17. B cell hyperactivity is a function of T cell derived cytokines in systemic lupus erythematosus.
al-Janadi M; Raziuddin S
J Rheumatol; 1993 Nov; 20(11):1885-91. PubMed ID: 7508509
[TBL] [Abstract][Full Text] [Related]
18. Autoregulatory function of interleukin-10-producing pre-naïve B cells is defective in systemic lupus erythematosus.
Sim JH; Kim HR; Chang SH; Kim IJ; Lipsky PE; Lee J
Arthritis Res Ther; 2015 Jul; 17(1):190. PubMed ID: 26209442
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.
Tyagi AM; Mansoori MN; Srivastava K; Khan MP; Kureel J; Dixit M; Shukla P; Trivedi R; Chattopadhyay N; Singh D
J Bone Miner Res; 2014 Sep; 29(9):1981-92. PubMed ID: 24677326
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Be1 and Be2 cells in systemic lupus erythematosus indicates elevated interleukin-10 producing CD5+ B cells.
Amel Kashipaz MR; Huggins ML; Lanyon P; Robins A; Powell RJ; Todd I
Lupus; 2003; 12(5):356-63. PubMed ID: 12765298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
